SG11201906134YA - Tyrosine amide derivatives as rho- kinase inhibitors - Google Patents

Tyrosine amide derivatives as rho- kinase inhibitors

Info

Publication number
SG11201906134YA
SG11201906134YA SG11201906134YA SG11201906134YA SG11201906134YA SG 11201906134Y A SG11201906134Y A SG 11201906134YA SG 11201906134Y A SG11201906134Y A SG 11201906134YA SG 11201906134Y A SG11201906134Y A SG 11201906134YA SG 11201906134Y A SG11201906134Y A SG 11201906134YA
Authority
SG
Singapore
Prior art keywords
parma
international
palermo
chiesi farmaceutici
chiesi
Prior art date
Application number
SG11201906134YA
Inventor
Alessandro Accetta
Fabio Rancati
Anna Maria Capelli
David Edward Clark
Patrizia Tisselli
Christine Edwards
Arnaud Jean Francois Auguste Cheguillaume
Gurdip Bhalay
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of SG11201906134YA publication Critical patent/SG11201906134YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

WO 18/ 138 293 Al R o (I) 0 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 02 August 2018 (02.08.2018) WIP0 I PCT omit VIII °nolo offi onolom mil ono (10) International Publication Number WO 2018/138293 Al (51) International Patent Classification: C07D 471/04 (2006.01) CO7D 487/04 (2006.01) A61K 31/437 (2006.01) CO7D 519/00 (2006.01) A61K 31/519 (2006.01) A61P 11/06 (2006.01) (21) International Application Number: PCT/EP2018/052009 (22) International Filing Date: 26 January 2018 (26.01.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 17153785.5 30 January 2017 (30.01.2017) EP (71) Applicant: CHIESI FARMACEUTICI S.P.A. [IT/IT]; Via Palermo, 26/A, 43122 PARMA (IT). (72) Inventors: ACCETTA, Alessandro; c/o CHIESI FAR- MACEUTICI S.p.A., Via Palermo, 26/A, 43122 PARMA (IT). RANCATI, Fabio; c/o CHIESI FARMACEUTICI S.p.A., Via Palermo, 26/A, 43122 PARMA (IT). CAPEL- LI, Anna Maria; c/o CHIESI FARMACEUTICI S.p.A., Via Palermo, 26/A, 43122 PARMA (IT). CLARK, David Edward; c/o CHIESI FARMACEUTICI S.p.A., Via Paler- mo, 26/A, 43122 PARMA (IT). TISSELLI, Patrizia; c/ o CHIESI FARMACEUTICI S.p.A., Via Palermo, 26/A, 43122 PARMA (IT). EDWARDS, Christine; c/o CHIESI FARMACEUTICI S.p.A., Via Palermo, 26/A, 43122 PAR- MA (IT). CHEGUILLAUME, Arnaud Jean Francois Auguste; c/o CHIESI FARMACEUTICI S.p.A., Via Paler- mo, 26/A, 43122 PARMA (IT). BHALAY, Gurdip; c/ o CHIESI FARMACEUTICI S.p.A., Via Palermo, 26/A, 43122 PARMA (IT). (74) Agent: MINOJA, Fabrizio; BIANCHETTI BRACCO MINOJA S.r.1., Via Plinio, 63, 20129 MILANO (IT). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) (54) Title: TYROSINE AMIDE DERIVATIVES AS RHO- KINASE INHIBITORS (57) : The invention relates to compounds of formula (I) inhibit- ing Rho Kinase that are bicyclic dihydropyrimidine-carboxamide deriv- atives, methods of preparing such compounds, pharmaceutical composi- tions containing them and therapeutic use thereof. Particularly the com- pounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary dis- eases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).
SG11201906134YA 2017-01-30 2018-01-26 Tyrosine amide derivatives as rho- kinase inhibitors SG11201906134YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17153785 2017-01-30
PCT/EP2018/052009 WO2018138293A1 (en) 2017-01-30 2018-01-26 Tyrosine amide derivatives as rho- kinase inhibitors

Publications (1)

Publication Number Publication Date
SG11201906134YA true SG11201906134YA (en) 2019-08-27

Family

ID=57914904

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201906134YA SG11201906134YA (en) 2017-01-30 2018-01-26 Tyrosine amide derivatives as rho- kinase inhibitors

Country Status (24)

Country Link
US (2) US10501461B2 (en)
EP (1) EP3573987B1 (en)
JP (1) JP7208142B2 (en)
KR (1) KR102429419B1 (en)
CN (1) CN110248939B (en)
AR (1) AR110782A1 (en)
AU (1) AU2018212593B2 (en)
BR (1) BR112019015707A2 (en)
CA (1) CA3047212A1 (en)
CL (1) CL2019002103A1 (en)
CO (1) CO2019008986A2 (en)
EA (1) EA039783B1 (en)
ES (1) ES2866152T3 (en)
IL (1) IL268004B (en)
MX (1) MX2019008895A (en)
MY (1) MY195588A (en)
PE (1) PE20191744A1 (en)
PH (1) PH12019501572A1 (en)
PL (1) PL3573987T3 (en)
SA (1) SA519402319B1 (en)
SG (1) SG11201906134YA (en)
TW (1) TW201831481A (en)
WO (1) WO2018138293A1 (en)
ZA (1) ZA201904239B (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019004685A (en) 2016-10-24 2019-08-21 Astrazeneca Ab 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer.
TWI794205B (en) 2017-01-30 2023-03-01 瑞典商阿斯特捷利康公司 Chemical compounds
US11407763B2 (en) * 2017-08-24 2022-08-09 Gwangju Institute Of Science And Technolgy Tryptophan hydroxylase inhibitor and pharmaceutical composition including same
WO2019048479A1 (en) * 2017-09-07 2019-03-14 Chiesi Farmaceutici S.P.A. Tyrosine analogues derivatives as rho- kinase inhibitors
KR20190043437A (en) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 Heterocylic compound as a protein kinase inhibitor
EP3728247B1 (en) 2017-12-18 2021-09-22 Chiesi Farmaceutici S.p.A. Oxadiazole derivatives as rho-kinase inhibitors
EP3728248B1 (en) 2017-12-18 2022-02-02 Chiesi Farmaceutici S.p.A. Azaindole derivatives as rho-kinase inhibitors
WO2019121223A1 (en) 2017-12-18 2019-06-27 Chiesi Farmaceutici S.P.A. Meta tyrosine derivatives as rho-kinase inhibitors
AR114926A1 (en) * 2018-06-13 2020-10-28 Chiesi Farm Spa AZAINDOL DERIVATIVES AS RHO-KINASE INHIBITORS
TW202019923A (en) * 2018-07-16 2020-06-01 義大利商吉斯藥品公司 Tyrosine amide derivatives as Rho-kinase inhibitors
WO2020081974A1 (en) * 2018-10-19 2020-04-23 Ohio State Innovation Foundation Nanocarriers for lung inflammation therapy
CN112979675B (en) * 2019-12-12 2023-12-19 维眸生物科技（上海）有限公司 Small molecular sulfur-containing heterocyclic compound
CN111217834B (en) * 2020-02-21 2021-10-26 维眸生物科技（上海）有限公司 Nitroxide derivatives of ROCK kinase inhibitors
MX2023004523A (en) 2020-10-22 2023-05-08 Woolsey Pharmaceuticals Inc Methods of treating 4-repeat tauopathies.
IL303641A (en) 2020-12-15 2023-08-01 Chiesi Farm Spa Dihydrofuropyridine derivatives as rho- kinase inhibitors
CA3202126A1 (en) 2020-12-15 2022-06-23 Fabio Rancati Dihydrofuropyridine derivatives as rho- kinase inhibitors
CN116600810A (en) 2020-12-15 2023-08-15 奇斯药制品公司 Dihydrofuranopyridine derivatives as RHO-kinase inhibitors
AU2022385051A1 (en) 2021-11-11 2024-06-20 Actualeyes Inc. Cryopreservation preparation for corneal endothelial cells and method for producing said cryopreservation preparation
WO2023110700A1 (en) 2021-12-13 2023-06-22 Chiesi Farmaceutici S.P.A. Dihydrofuropyridine derivatives as rho-kinase inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7737153B2 (en) 2002-10-28 2010-06-15 Bayer Schering Pharma Aktiengesellschaft Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors
DE10357510A1 (en) 2003-12-09 2005-07-07 Bayer Healthcare Ag Heteroaryl-substituted benzenes
DE102004017438A1 (en) * 2004-04-08 2005-11-03 Bayer Healthcare Ag Hetaryloxy-substituted phenylaminopyrimidines
EP1756092A4 (en) 2004-06-17 2009-12-02 Smithkline Beecham Corp Novel inhibitors of rho-kinases
EP2234618A4 (en) 2007-12-21 2011-04-27 Scripps Research Inst Benzopyrans and analogs as rho kinase inhibitors
CN102159547A (en) 2008-09-18 2011-08-17 安斯泰来制药株式会社 Heterocyclic carboxamide compounds
ES2622519T3 (en) 2010-07-14 2017-07-06 Novartis Ag Heterocyclic components of the IP receptor agonist
BR112013030302B1 (en) * 2011-06-10 2021-08-24 Chiesi Farmaceutici S.P.A. COMPOUND, PHARMACEUTICAL COMPOSITION, USE OF A COMPOUND, COMPOSITION OF A COMPOUND AND DEVICE
AU2014211580B2 (en) 2013-01-29 2018-05-10 Redx Pharma Plc Pyridine derivatives as soft ROCK inhibitors
US9902702B2 (en) * 2014-07-15 2018-02-27 Bristol-Myers Squibb Company Spirocycloheptanes as inhibitors of rock

Also Published As

Publication number Publication date
KR20190112000A (en) 2019-10-02
WO2018138293A1 (en) 2018-08-02
PH12019501572A1 (en) 2020-03-16
IL268004A (en) 2019-09-26
MY195588A (en) 2023-02-02
JP2020505328A (en) 2020-02-20
KR102429419B1 (en) 2022-08-05
US10954236B2 (en) 2021-03-23
PE20191744A1 (en) 2019-12-12
CL2019002103A1 (en) 2019-12-27
PL3573987T3 (en) 2021-08-30
SA519402319B1 (en) 2022-03-02
IL268004B (en) 2021-03-25
EA039783B1 (en) 2022-03-14
US20200079774A1 (en) 2020-03-12
AU2018212593A1 (en) 2019-07-25
ZA201904239B (en) 2020-12-23
TW201831481A (en) 2018-09-01
CN110248939B (en) 2022-05-17
CA3047212A1 (en) 2018-08-02
BR112019015707A2 (en) 2020-03-24
AR110782A1 (en) 2019-05-02
CO2019008986A2 (en) 2020-01-17
ES2866152T3 (en) 2021-10-19
EP3573987A1 (en) 2019-12-04
CN110248939A (en) 2019-09-17
AU2018212593B2 (en) 2022-05-19
EP3573987B1 (en) 2021-03-10
JP7208142B2 (en) 2023-01-18
EA201991793A1 (en) 2020-03-20
US20180215758A1 (en) 2018-08-02
US10501461B2 (en) 2019-12-10
MX2019008895A (en) 2019-09-13

Similar Documents

Publication Publication Date Title
SG11201906134YA (en) Tyrosine amide derivatives as rho- kinase inhibitors
SG11201810983PA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201907544VA (en) Jak inhibitors containing a 4-membered heterocyclic amide
SG11201900799XA (en) Pyridopyrimdinone cdk2/4/6 inhibitors
SG11201811414TA (en) Heterocyclic compounds as immunomodulators
SG11201809064QA (en) Chimeric neurotoxins
SG11201901747VA (en) Inhibitors of cellular metabolic processes
SG11201902938TA (en) Compounds, devices, and uses thereof
SG11201804152RA (en) Heterocyclic compounds as immunomodulators
SG11201804098TA (en) Purinones as ubiquitin-specific protease 1 inhibitors
SG11201811470PA (en) Pyrazolopyrimidine derivatives as kinase inhibitor
SG11201809342YA (en) Pyrimidine compounds as jak kinase inhibitors
SG11201908640TA (en) Pyrrolidinones and a process to prepare them
SG11201909960UA (en) Methods for improving memory and cognition and for treating memory and cognitive disorders
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201804589TA (en) Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
SG11201805387RA (en) Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists
SG11201907356SA (en) Piperidine-substituted mnk inhibitors and methods related thereto
SG11201908114UA (en) Pyrimidopyrimidinones useful as wee-1 kinase inhibitors
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201809671PA (en) Imidazolone compounds as human neutrophil elastase inhibitors
SG11201908091QA (en) Aqueous anti-pd-l1 antibody formulation
SG11201903091VA (en) Quinoxaline compounds as type iii receptor tyrosine kinase inhibitors